Abstract
After much initial debate for and against the role of amyloid in Alzheimers disease (AD), mutations on the amyloid precursor protein (APP) and processing pathways that increase levels of the amyloid b peptide of 42 residues (Aβ42) have established that faulty function or processing of these proteins are responsible for AD pathogenesis. Given the neurotoxicity of aggregates of Ab42, the central role of this peptide in AD pathogenesis is self evident. In this article, I summarize the major pieces of evidence adduced to support the amyloid cascade hypothesis and point out their limitations
Keywords: APP mutations, neurodegenerative disease, oxidative stress, apolipoprotein, presenilin
Current Alzheimer Research
Title: Has the Amyloid Cascade Hypothesis for Alzheimers Disease been Proved?
Volume: 3 Issue: 1
Author(s): John Hardy
Affiliation:
Keywords: APP mutations, neurodegenerative disease, oxidative stress, apolipoprotein, presenilin
Abstract: After much initial debate for and against the role of amyloid in Alzheimers disease (AD), mutations on the amyloid precursor protein (APP) and processing pathways that increase levels of the amyloid b peptide of 42 residues (Aβ42) have established that faulty function or processing of these proteins are responsible for AD pathogenesis. Given the neurotoxicity of aggregates of Ab42, the central role of this peptide in AD pathogenesis is self evident. In this article, I summarize the major pieces of evidence adduced to support the amyloid cascade hypothesis and point out their limitations
Export Options
About this article
Cite this article as:
Hardy John, Has the Amyloid Cascade Hypothesis for Alzheimers Disease been Proved?, Current Alzheimer Research 2006; 3 (1) . https://dx.doi.org/10.2174/156720506775697098
DOI https://dx.doi.org/10.2174/156720506775697098 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aluminofluoride Complexes: Phosphate Analogues and a Hidden Hazard for Living Organisms
Current Inorganic Chemistry (Discontinued) Considering Autotaxin Inhibitors in Terms of 2D-QSAR and 3D-Mapping- Review and Evaluation
Current Medicinal Chemistry Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design Identification and Temporal Characterization of Features Associated with the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity
Current Medicinal Chemistry Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Current Alzheimer Research Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Why Is Homocysteine Toxic for the Nervous and Immune Systems?
Current Aging Science Lactoferrin Suppresses Decreased Locomotor Activities by Improving Dopamine and Serotonin Release in the Amygdala of Ovariectomized Rats
Current Molecular Pharmacology Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers
Current Psychiatry Reviews BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease
Current Alzheimer Research Cannabis Epidemiology: A Selective Review
Current Pharmaceutical Design Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Neurotransmitter Effects in Human Immunodeficiency Virus (HIV) and Simian Immuno-Deficiency Virus (SIV) Infection
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Blue-Enriched Lighting for Older People Living in Care Homes: Effect on Activity, Actigraphic Sleep, Mood and Alertness
Current Alzheimer Research Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Humanin; A Defender Against Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued)